Table 2.

Stratification analysis of risk genotypes with neuroblastoma susceptibility

Variables	rs3811464 (cases/controls)		AOR (95% CI)a	P a	rs34787247 (cases/controls)		AOR (95% CI)a	P a	Combined risk genotypes (case/controls)		AOR (95% CI)a	P a
	GG/GA	AA			GG	GA/AA			0	1‐4
Age, month
≤18	181/413	8/12	1.50 (0.60‐3.75)	.381	126/319	63/106	1.51 (1.04‐2.19)	.031	67/186	122/239	1.42 (0.99‐2.02)	.055
>18	301/627	15/18	1.74 (0.87‐3.51)	.120	227/502	89/143	1.38 (1.01‐1.87)	.042	125/279	191/366	1.17 (0.89‐1.54)	.271
Gender
Females	203/439	10/9	2.41 (0.97‐6.04)	.060	149/340	64/108	1.35 (0.94‐1.95)	.105	81/200	132/248	1.31 (0.94‐1.83)	.109
Males	279/601	13/21	1.34 (0.66‐2.72)	.415	204/481	88/141	1.47 (1.08‐2.01)	.015	111/265	181/357	1.21 (0.91‐1.61)	.184
Sites of origin
Adrenal gland	167/1040	6/30	1.28 (0.52‐3.13)	.593	124/821	49/249	1.31 (0.91‐1.88)	.147	69/465	104/605	1.17 (0.84‐1.62)	.359
Retroperitoneal	138/1040	9/30	2.23 (1.04‐4.81)	.041	105/821	42/249	1.33 (0.90‐1.95)	.152	51/465	96/605	1.44 (1.003‐2.07)	.048
Mediastinum	129/1040	6/30	1.67 (0.68‐4.11)	.262	94/821	41/249	1.43 (0.96‐2.12)	.078	55/465	80/605	1.13 (0.78‐1.62)	.528
Others	40/1040	2/30	1.67 (0.38‐7.27)	.494	27/821	15/249	1.84 (0.96‐3.51)	.066	15/465	27/605	1.38 (0.73‐2.63)	.326
Clinical stages
I + II + 4s	237/1040	13/30	1.93 (0.99‐3.75)	.054	177/821	73/249	1.35 (1.00‐1.84)	.054	87/465	163/605	1.44 (1.08‐1.91)	.014
III + IV	222/1040	10/30	1.59 (0.76‐3.31)	.216	162/821	70/249	1.43 (1.05‐1.97)	.025	97/465	135/605	1.07 (0.80‐1.43)	.646

Abbreviations: AOR, adjusted odds ratio; CI, confidence interval.

Significance of bold values are the P values less than 0.05 or the 95% CIs excluded 1.

^aAdjusted for age and gender, omitting the corresponding stratify factor.